Astellas Providing Refunds for 340B Overcharges from Q3 2020 Through Q2 2021

Astellas building mounted sign
Astellas is issuing 340B covered entities refunds for overcharges on Xtandi and Myrbetriq for the period from Q3 2020 through Q2 2021.

Astellas Pharma is issuing 340B covered entities refunds for overcharges on three NDCs for its prostate cancer treatment Xtandi and on four NDCs for its overactive bladder medication Myrbetriq for the period from Q3 2020 through Q2 2021.

Astellas posted 

Read More »

Multiple Developments in 340B Contract Pharmacy Lawsuit Appeals

plaintiff table in a courtroom
There has been a burst of activity in federal appeals courts in drug manufacturers' 340B contract pharmacy lawsuits.

A federal appeals court in Chicago has told a lower court in Indianapolis to issue a final judgement in drug manufacturer Lilly’s 340B contract pharmacy lawsuit to clear the way for the case’s next phase.

An appeals court in Philadelphia

Read More »

Lilly Providing Refunds for 340B Overcharges During Q3 2019

Lilly outdoor sign
Drug company Lilly is providing refunds for 340B overcharges on 14 NDCs during 3Q 2019.

Drug manufacturer Lilly is giving 340B covered entities refunds for overcharges on 14 NDCs during Q3 2019 after restating Medicaid average manufacturer prices and best prices “to account for lagged transactional data,” the company says on a notice on the

Read More »

340B Report Publisher and CEO Slafsky: 340B Contract Pharmacy Program Has Fractured Into 17 Pieces

shattered glass
Drug manufacturers' 340B contract pharmacy actions have seemingly fractured the 340B program into pieces, 340B Publisher and CEO Ted Slafsky says.

“The 340B contract pharmacy program has seemingly fractured into 17 programs, one governed by the federal government and 16 others with their own standards determined by pharmaceutical manufacturers,” 340B Publisher and CEO Ted Slafsky observes in his latest column for

Read More »

While All Eyes are on 340B Contract Pharmacy Battle, Federal Appeals Court Hears Arguments in Key Case Challenging HRSA’s Patient Definition

Genesis Health Care office sign and facility
A South Carolina health center's lawsuit, now before a federal appeals court, challenges one of of the 340B program's basic elements—the definition of a “patient” eligible to receive 340B drugs.

Part 1 of Two-Part Deep Dive into One of the Most Important and Contentious Areas of 340B Program

While much of the 340B community’s attention has been focused on the contract pharmacy suits winding through the federal court system, there

Read More »

340B Patient Definition Is at the Heart of Case Debated Before Federal Appeals Court

USCA Fourth Circuit court building
A federal appeals court in Richmond, Va., heard arguments last month in a case involving the legality of the 340B program definition of "patient."

Part 2 of a Two-Part Series About One of the Most Important and Contentious Areas of the 340B Program. Read Part 1 here.

An attorney for a South Carolina health center asked a federal appeals court in Richmond, Va., last

Read More »

Influential 340B Lawmaker Upton Announces Retirement

Rep. Fred Upton speaks at a House hearing
U.S. Rep. Fred Upton (R-Mich.), a former House Energy & Commerce Committee chair who 340B entities call a close ally, is retiring from Congress.

U.S. Rep. Fred Upton (R-Mich.), a former House Energy & Commerce Committee chair who 340B entities call a close ally, announced on Tuesday he will not seek another term in Congress.

“Even the best of stories has a last chapter,”

Read More »

Influential Drug Cost-Effectiveness Organization Endorses Partially Lifting 340B Orphan Drug Exclusion

Institute for Clinical and Economic Review wordmark
Policymakers should consider narrowing the 340B orphan drug exemption, ICER said today in a new report.

The exclusion of 340B pricing for some hospitals on drugs to treat orphan conditions and diseases could be partially eliminated to slow “the rapid growth in approved rare disease treatments” and “their cumulative affordability to the health system,” an influential

Read More »

House Passes Bill to Limit Insulin Co-Pays, but the Way Forward in Senate Is Unclear

Senate Majority Leader Chuck Schumer (D-N.Y.)
Senate Majority Leader Chuck Schumer (D-N.Y.) said last month "the Senate will vote on a bill to fix" the skyrocketing cost of insulin. The House last week passed a bill limiting cost-sharing for insulin.

The U.S. House passed a bill late last week limiting cost-sharing for insulin under private health insurance and Medicare Part D.

H.R. 6833 caps cost-sharing under private health insurance for a month’s supply of selected insulin products at $35 or

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report